HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 274 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.48 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,037 | +228.5% | 105,680 | +210.1% | 0.01% | +250.0% |
| Q2 2023 | $1,229 | -66.2% | 34,080 | -64.2% | 0.00% | -60.0% |
| Q1 2023 | $3,633 | -54.9% | 95,141 | -32.8% | 0.01% | -54.5% |
| Q4 2022 | $8,059 | -99.9% | 141,641 | -60.5% | 0.01% | -45.0% |
| Q3 2022 | $14,167,000 | -33.6% | 358,300 | -26.2% | 0.02% | -20.0% |
| Q2 2022 | $21,349,000 | +157.7% | 485,200 | +133.6% | 0.02% | +150.0% |
| Q1 2022 | $8,283,000 | +63.5% | 207,700 | +64.8% | 0.01% | +66.7% |
| Q4 2021 | $5,066,000 | -18.7% | 126,000 | -17.8% | 0.01% | -25.0% |
| Q3 2021 | $6,232,000 | -77.8% | 153,200 | -77.3% | 0.01% | -77.1% |
| Q1 2021 | $28,087,000 | +24.5% | 673,700 | +27.6% | 0.04% | +45.8% |
| Q4 2020 | $22,556,000 | +62.6% | 528,129 | +0.1% | 0.02% | +71.4% |
| Q3 2020 | $13,868,000 | -48.7% | 527,700 | -47.7% | 0.01% | -39.1% |
| Q2 2020 | $27,030,000 | +364.6% | 1,008,200 | +211.8% | 0.02% | +283.3% |
| Q1 2020 | $5,818,000 | -73.1% | 323,400 | -73.5% | 0.01% | -64.7% |
| Q4 2019 | $21,606,000 | +174.2% | 1,218,600 | +165.7% | 0.02% | +142.9% |
| Q2 2019 | $7,879,000 | -34.7% | 458,600 | -38.8% | 0.01% | -36.4% |
| Q1 2019 | $12,065,000 | +170.8% | 749,400 | +146.0% | 0.01% | +120.0% |
| Q4 2018 | $4,456,000 | -58.5% | 304,600 | -48.4% | 0.01% | -54.5% |
| Q3 2018 | $10,731,000 | -66.8% | 590,600 | -66.7% | 0.01% | -38.9% |
| Q2 2018 | $32,321,000 | +84.7% | 1,771,800 | +98.3% | 0.02% | -5.3% |
| Q1 2018 | $17,502,000 | +17.3% | 893,400 | +21.3% | 0.02% | +18.8% |
| Q4 2017 | $14,924,000 | +10192.4% | 736,600 | +4910.9% | 0.02% | – |
| Q4 2016 | $145,000 | -88.0% | 14,700 | -85.3% | 0.00% | -100.0% |
| Q3 2016 | $1,208,000 | -66.0% | 100,000 | -73.3% | 0.00% | -71.4% |
| Q1 2016 | $3,551,000 | +2176.3% | 375,000 | +3132.8% | 0.01% | – |
| Q3 2015 | $156,000 | -95.6% | 11,600 | -92.6% | 0.00% | -100.0% |
| Q2 2015 | $3,559,000 | -34.6% | 157,600 | -58.6% | 0.01% | -33.3% |
| Q1 2015 | $5,438,000 | +625.1% | 380,800 | +390.1% | 0.01% | +500.0% |
| Q4 2014 | $750,000 | -73.7% | 77,700 | -73.1% | 0.00% | -71.4% |
| Q2 2014 | $2,856,000 | +66.0% | 289,062 | +113.5% | 0.01% | +75.0% |
| Q1 2014 | $1,720,000 | -61.8% | 135,400 | -54.9% | 0.00% | -63.6% |
| Q4 2013 | $4,497,000 | – | 300,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 14,092,771 | $256,066,000 | 16.64% |
| BB BIOTECH AG | 8,247,860 | $149,864,000 | 3.97% |
| MSD Partners, L.P. | 2,245,000 | $40,792,000 | 3.07% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 428,633 | $5,969,000 | 2.84% |
| First Light Asset Management, LLC | 885,523 | $16,090,000 | 2.60% |
| SNYDER CAPITAL MANAGEMENT L P | 2,387,350 | $43,378,000 | 1.93% |
| Sterling Global Strategies LLC | 22,000 | $400,000 | 1.74% |
| Taylor Wealth Management Partners | 221,380 | $4,022,000 | 1.71% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,228,399 | $167,680,000 | 1.68% |
| DOHENY ASSET MANAGEMENT /CA | 124,393 | $2,260,000 | 1.18% |